The study of Bedaquiline implementation under the National TB Programme at NITRD, central India

Abstract

Bedaquiline (BDQ) was approved for treatment of drug-resistant TB (DR-TB) under the Conditional Access Programme (CAP) of the Revised National Tuberculosis Control Programme (RNTCP). We present early efficacy and safety of BDQ-containing regimens for DR-TB.